Early-phase study of an injected cancer treatment for advanced tumors
Part of Cancer clinical trials.
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and sign informed consent willingly
- Have confirmed cancer (solid tumor is preferred for the main dose-adding part) and measurable disease on scans
- Provide tumor tissue for biomarker testing (fresh biopsy preferred; otherwise samples within 2 years)
- Have recovered from prior cancer treatment side effects to mild levels (mostly grade 0–1)
- Be in good overall health: ECOG 0–1, expected survival of at least 3 months, and acceptable blood and organ test results
- Use effective birth control from consent through 6 months after the last dose (and not be pregnant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug (LNF1901) for people with advanced cancers that haven't responded to standard treatments. The goal is to see if it is safe and how well it works, and it might help control the cancer or shrink tumors.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
This trial tests LBL-024 in people with advanced cancer to see how it works and how safe it is. You may consider it if you are well enough for study visits and have time to complete at least about 12 weeks of follow-up.
This Phase 1 study tests BAT8008 injection to see how safe it is, how well the body handles it, and how it affects the body’s drug levels. It’s for adults with advanced or metastatic solid tumors that are not responding to, or can’t be tolerated with, standard treatments.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.